Bill > SB1848

This bill expands the ability of certain healthcare providers to directly administer buprenorphine, a medication used to treat opioid use disorder, either as a standalone product (mono) or without naloxone, a drug that can reverse opioid overdoses. Specifically, it allows these providers, acting within their professional scope and under a physician's order, to administer buprenorphine for substance use disorder treatment, with the caveat that it cannot be dispensed for self-administration away from the dispensing location. The bill also clarifies that prescribing buprenorphine products to nursing mothers or prescribing an injectable mono product does not prevent these healthcare providers from prescribing buprenorphine without naloxone for opioid use disorder treatment, thereby removing a previous restriction for these specific patient groups.

Health and Social Services

https://wapp.capitol.tn.gov/apps/Billinfo/default.aspx?BillNumber=SB1848&ga=114